Submitted by Anonymous (not verified) on 22 November 2024 - 13:18
Opinion/decision on a Paediatric investigation plan (PIP): Giapreza, Angiotensin II (LJPC-501), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Cardiovascular diseases, PIP number: P/0415/2023
Source: